9/10/2021 7:29:53 AM
BeyondSpring Q2 Loss Per Share $0.46 Vs Loss $0.49 Last Year
6/4/2021 7:16:55 AM
BeyondSpring Doses First Patient In A Triple Combination Study With Plinabulin
5/24/2021 7:38:09 AM
BeyondSpring Announces Poster Presentation Of An Investigator-initiated Phase 1 Study
4/1/2021 12:19:35 AM
BeyondSpring Submits NDA To FDA And China NMPA For Plinabulin And G-CSF Combination For Chemotherapy-Induced Neutropenia
12/17/2020 8:13:06 AM
BeyondSpring Appoints Jeffrey Vacirca To Its Board
11/19/2020 8:21:57 AM
BeyondSpring Prices Public Offering Of 7.50 Mln Ordinary Shares At $10/Shr
11/13/2020 7:25:23 AM
BeyondSpring: Seed Therapeutics Enters Research Collaboration, License Agreement With Eli Lilly
9/22/2020 8:42:53 AM
BeyondSpring Appoints Elizabeth Czerepak As CFO
9/8/2020 7:18:44 AM
BeyondSpring Receives Breakthrough Therapy Designations From Both U.S. FDA And China NMPA For Plinabulin
6/19/2020 5:39:28 AM
BeyondSpring Prices Public Offering Of 1.93 Mln Ordinary Shares At $13/Shr
6/15/2020 7:19:36 AM
BeyondSpring Reports Positive Topline Interim Results From PROTECTIVE-2 Phase 3 Trial
5/13/2020 8:14:14 AM
BeyondSpring Granted New U.S. Patent For Plinabulin To Treat Severe Chemotherapy-Induced Neutropenia From Taxane